On April 13^th , 2022, National Medical Products Administration announced the good news that Livzon Rapid Test for 2019-nCoV-2 Antigen (Lateral Flow) was approved and to be listed with registration certificate No. 20223400470. The product was independently researched and developed by Zhuhai Livzon Diagnostics Inc., a holding subsidiary of Livzon Pharmaceutical Group. It can effectively relieve the pressure of COVID- testing in domestic market and help to prevent and control the COVID epidemic.

On March 11^th , the State Council issued the notice of "Rapid Test for 2019-nCoV-2 Antigen Application Plan (For Trial Implementation)", decided to add Rapid Test for 2019-nCoV-2 Antigen as a supplement testing way on the basis of current nucleic acid testing. Zhuhai Livzon Diagnostics Inc., immediately launched the registration process. Before that, Livzon Rapid Test for 2019-nCoV-2 Antigen (Lateral Flow) has obtained registration certificates of EU CE, UK, Indonesia and Thailand, as well as the white list of France, Germany, Austria and other countries or regions. The product has been well sold to many countries and regions such as EU and Asia Pacific.

Livzon Rapid Test for 2019-nCoV-2 Antigen (Lateral Flow) is used for in vitro qualitative detection of 2019-nCoV-2 Nucleocapsid antigen in nasopharyngeal swabs, oropharyngeal swabs and nasal swabs.

It is applicable to all-level medical and health institutions, isolated people under observation and residents with self-test demands. The test results could be obtained within 15 ~ 20 minutes without equipment with advantages such as rapid testing, accurate results, simple operation and user-friendly design. Compared with the public data of similar listed products in the market, Livzon Rapid Test for 2019-nCoV-2 Antigen (Lateral Flow) is of higher coincidence rate with nucleic acid testing results.